MPS-1 inhibitors

The present invention covers crystalline, anhydrous (2R)-2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(methylsulfonyl)-phenyl]-amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]propan-amide 4-toluenesulfonate, and crystalline (2R)-2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(methylsulfonyl)-phenyl]-amino}[1,...

Full description

Saved in:
Bibliographic Details
Main Authors STEIN, SVEN, DWORACEK, SYLVIA, BOEHMER, LARS, HUCKE, FRANK, HOLKENJANS, WIEBKE, OLENIK, BRITTA, BECKER, GUIDO, BIERER, DONALD, PAULSEN, HOLGER, ZOELLER, THOMAS, MUENSTER, UWE
Format Patent
LanguageChinese
English
Published 01.01.2018
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention covers crystalline, anhydrous (2R)-2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(methylsulfonyl)-phenyl]-amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]propan-amide 4-toluenesulfonate, and crystalline (2R)-2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(methylsulfonyl)-phenyl]-amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]propanamide 4-toluenesulfonate monohydrate, as compoundsper se, a method of preparing said crystalline, anhydrous compound, pharmaceutical compositions and pharmaceutical combinations comprising said crystalline, anhydrous compound, and uses of said crystalline, anhydrous compound in the treatment or prophylaxis of a cancer, in particular pancreatic cancer, glioblastoma, ovarian cancer, non-small cell lung carcinoma, breast cancer, and/or gastric cancer.
Bibliography:Application Number: TW20176118459